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Abstract
Purpose The aim of this study was to investigate the clinical
relevance of potentially inappropriate medications (PIMs),
identified by the STOPP criteria, and potential prescribing
omissions (PPOs), identified by the START criteria, and to
identify predictors for clinically relevant PIMs and PPOs.
Methods The STOPP and STARTcriteria were applied on the
medication lists of 200 older hip fracture patients, consecu-
tively recruited to a randomized controlled study in 2009. For
each identified PIM and/or PPO, the clinical relevance was
assessed at the individual level, using medical records from
both hospital and primary care as well as data collected in the
original study.
Results A total of 555 PIMs/PPOs were identified in 170
(85%) patients (median age: 85 years, 67% female), 298
(54%) of which, in 141 (71%) patients, were assessed as
clinically relevant. A greater proportion of PIMs than
PPOs were clinically relevant: 71% (95% CI: 66%; 76%)
vs. 32% (27%; 38%). A greater proportion of PPOs than
PIMs could not be assessed with available information:
38% (32%; 44%) vs. 22% (17%; 27%). Number of drugs
and multidose drug dispensing, but not age, sex, cognition,
or nursing home residence, were associated with ≥1 clini-
cally relevant PIMs/PPOs.
Conclusions The present study illustrates that one in two
PIMs/PPOs identified by the STOPP/STARTcriteria is clearly
clinically relevant, PIMs being clinically relevant to a greater
extent than PPOs. Based on available information, the clinical
relevance could not be determined in a non-negligible propor-
tion of PIMs/PPOs. Number of drugs and multidose drug
dispensing were associated with ≥1 clinically relevant
PIMs/PPOs.
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Introduction
Prescribing of drugs is a challenge, particularly in older people
who are sensitive to drug effects and often suffer from multi-
ple morbidities. In fact, it is well-known that suboptimal phar-
macotherapy is common in older people, such as treatment
with inappropriate drugs or dosages, and/or omissions of
drugs which the patient would probably benefit from [1–3].
In order to improve the quality of drug treatment, explicit
criteria may serve as tools to identify potential problems, as
potentially inappropriate medications (PIMs) and potential
prescription omissions (PPOs). Some criteria can be applied
on the drug list alone, whereas others require clinical informa-
tion such as diagnoses and laboratory parameters [4–7]. The
screening tool of older persons’ potentially inappropriate pre-
scriptions (STOPP) and the screening tool to alert to right
treatment (START) criteria belong to the ones requiring clin-
ical information [8]. These criteria have been used in several
studies describing drug treatment quality [9, 10]. The original
version was developed to be applied in the clinical situation by
the attending physician, and provide 65 criteria for potentially
inappropriate drugs and 22 criteria for potentially missing
* Susanna M. Wallerstedt
susanna.wallerstedt@pharm.gu.se
1 Department of Internal Medicine, Sahlgrenska University Hospital,
Gothenburg, Sweden
2 Department of Pharmacology, Sahlgrenska Academy, University of
Gothenburg, SE-413 90 Gothenburg, Sweden
3 Department of Clinical Pharmacology, Sahlgrenska University
Hospital, Gothenburg, Sweden
Eur J Clin Pharmacol (2017) 73:499–505
DOI 10.1007/s00228-016-2188-9
drugs, respectively. An updated, more extensive, version has
been published [11].
To apply the first version of the STOPP/STARTcriteria has
been estimated to require an additional 3 min for the
physician-patient consultation [12]. However, even though
the additional minutes required may be few under optimal
conditions, constraints of time may be an obstacle for imple-
mentation [13]. Indeed, as information on medical conditions
and medication history within an electronic patient record is
not always easily retrieved [14], systematically checking an
extensive set of criteria may be time-consuming.
To facilitate for physicians to take advantage of criteria in
clinical practice, the first step may be to minimize the extra
time needed for the application. This can be achieved by fo-
cusing on frequently occurring criteria, easy to assess given
available information in the medical records, and often of
clinical relevance. However, although experts have often
assessed available criteria sets for relevance, credibility, and
acceptability at the general level [15, 16], less is known about
the extent of their clinical relevance at the individual level.
In addition to easily applicable criteria requiring a mini-
mum of time, physicians may want to know which patients
would be most worthwhile to assess a bit further. Indeed,
potentially suboptimal drug treatment has been associated
with age, sex, and number of drugs [17]. However, less is
known on patient characteristics associated with clinically rel-
evant prescribing problems, a question of superior interest to
the attending physician.
The aim of this study was to investigate the clinical rele-
vance of PIMs and PPOs identified by the STOPP/START
criteria, and to identify predictors for clinically relevant
PIMs/PPOs.
Methods
The present study was performed within a cohort of older hip
fracture patients, consecutively recruited to a randomized con-
trolled study in the departments of orthopedics, geriatrics, and
medicine at Sahlgrenska University Hospital in 2009 [18].
Inclusion criteria in the original study were patients, ≥65 years
of age, who had undergone surgery for a hip fracture at
Sahlgrenska University Hospital, were residing in the
Gothenburg area, and provided informed consent. In all, 200
out of 253 patients undergoing hip fracture surgery during the
inclusion period were included in the original study; 23 de-
clined participation, 14 did not fulfill the other inclusion
criteria, 10 were deceased before inclusion, and six were ex-
cluded because of other reasons.
In the original study, the medication list at study entry (ad-
mission to hospital) was determined.When a patient could not
report satisfactorily on his/her medications, the Swedish
Register of Dispensed Drugs (Läkemedelsförteckningen)
was consulted, holding information available in clinical prac-
tice for the attending physician on prescribed drugs purchased
from any Swedish pharmacy during the preceding 15 months.
Drugs used regularly and as needed were included. Drugs for
external use were included only if having potential systemic
effects. Thus, topical medications, tear substitutes, and dental
fluoride preparations were excluded.
In the present study, the STOPP and START criteria were
applied on the medication list determined in the original study,
identifying PIMs and PPOs. The clinical relevance of each PIM/
PPO was assessed at the individual level. If the expected benefit
of a particular medication was judged to outweigh the potential
harm, such as an antipsychotic drug in a patient with schizophre-
nia, the PIM was assessed as not clinically relevant. Similarly, if
there was a clinical reason not to treat the patient with the drug,
such as an adverse drug reaction or a contraindication, the PPO
was assessed as not clinically relevant. When the information
available was not sufficient to determine the clinical relevance,
the PIM/PPO was categorized as not assessable.
The assessments were independently performed by one
general practitioner and one geriatrician in 2012–2013. They
were based on (1) medical records from both hospital and
primary care and (2) previously collected data including in-
formation on risk of falls, cognition, residence, and glomerular
filtration rate. The latter, estimated with the Cockcroft-Gault
equation, was dichotomized as either ≥50 or <50 ml/min to fit
the STOPP and START criteria. In a final consensus discus-
sion, the two specialist physicians reached agreement on iden-
tified PIMs/PPOs, and the clinical relevance of these.
Statistics
All statistical analyses were performed with SPSS (IBMSPSS
Statistics for Windows, Version 17.0, Armonk, NY). We used
the MannWhitney and the chi-square tests for comparisons of
characteristics between patients with and without ≥1 clinically
relevant PIMs/PPOs, and 95% confidence intervals (CI) were
calculated for proportions. Kappa statistics was used to assess
inter-rater agreement. Logistic regression was performed to
obtain odds ratios (and 95% CI) for ≥1 PIMs/PPOs, as well
as ≥1 clinically relevant PIMs/PPOs. In the main analysis, due
to the fact that we wanted to identify quickly adoptable
criteria, we chose to categorize not assessable PIMs/PPOs as
not clinically relevant. A sensitivity analysis was performed
where not assessable PIMs/PPOs were categorized as clinical-
ly relevant. Covariates included in the analysis were age, sex,
cognition (defined as impaired or not), residence (defined as
nursing home or not; nursing home residence reflecting that
the patient needed help with daily living activities), multidose
drug dispensing (defined as having ≥1 drugs prescribed via
this system; associated with quality of drug treatment in prior
studies [19–21]), and number of drugs (a proxy for burden of
disease [22]).
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Results
Characteristics of patients by results on STOPP/STARTcriteria
are presented in Table 1. Summarized, the patients had a mean
age of 84.5 years, ranging from 65 to 98 years, and 133 (67%)
were women. The mean number of drugs in the medication list
was 7.2 ± 3.9 (range 0–21). Multidose drug dispensing, was
consistently more common in patients with PIMs/PPOs, irre-
spective of their being clinically relevant or not. These patients
also had more drugs in their medication list.
A total of 555 PIMs/PPOs were identified in 170 (85%)
patients; 298 (54%) of which, in 141 (71%) patients, were
assessed as clinically relevant. The inter-rater agreement was
moderate (kappa 0.52). A greater proportion of PIMs than
PPOs was clinically relevant: 217 in 305 (71% (95% CI: 66%;
76%)) vs. 81 in 250 (32% (27%; 38%)). The median number of
clinically relevant PIMs and PPOs per patient was 1 (mean 1.09,
range 0–6) and 0 (mean 0.41, range 0–3), respectively.
In all, 160 (29%) PIMs/PPOs were not assessable. A great-
er proportion of PPOs than PIMs could not be determined
with available information: 94 (38% (32%; 44%)) vs. 66
(22% (17%; 27%).
For six (9.2%) out of 65 STOPP and two (9.1%) out of 22
START criteria, ≥10 (5%) patients had a clinically relevant
PIM and PPO, respectively (Table 2). For 37 (57%) STOPP
and 17 (77%) START criteria, ≥1 (≥0.5%) patients had a clin-
ically relevant PIM and PPO, respectively.
The most frequently occurring PIMs were benzodiazepines
in those prone to falls, and aspirin either without cardiovascular
disease or at a dose >150 mg/day. The PIMs long-acting ben-
zodiazepines and aspirin at a dose >150 mg/day were clinically
relevant in all but one patient. As for loop diuretics without
clinical signs of heart failure and for bensodiazepines, no PIM
was assessed as not clinically relevant. Although not frequently
occurring (5.5%), the PIM vasodilator drugs in patients with
postural hypotension were clinically relevant in 82% of the
cases. Among patients prone to falls, the clinical relevance of
the frequent PIMs concerning benzodiazepines, neuroleptics,
and opiates could not be determined in 35–44% of the cases.
The most frequently occurring PPOs were osteoporosis
without calcium and vitamin D supplementation, and
chronic atrial fibrillation without warfarin; 16% and 24%
of which, respectively, were assessed as clinically rele-
vant. Clinical relevance could not be determined in 77%
of the cases for calcium and vitamin D. Among frequent
PPOs in patients with cardiovascular disease, the clinical
relevance could not be determined in 21–33% of the cases
when it came to treatment with angiotensin converting
enzyme inhibitors, warfarin, beta-blockers, or statins.
In the main analysis, as well as the sensitivity analysis, the
odds for ≥1 clinically relevant PIMs/PPOs were greater for
patients with multidose drug dispensing and increased by the
number of drugs in the medication list (Table 3). Age, sex,
cognition, and nursing home residence was not statistically
significantly associated with suboptimal drug treatment.
Discussion
Our study shows that, at the overall level, one in two
PIMs/PPOs, identified with the STOPP/START criteria, is
clinically relevant according to the easily retrievable docu-
mentation. PIMs are clinically relevant to a greater extent,
and PPOs are more often hard to assess concerning clinical
relevance. The prevalence of over- and undertreatment ac-
cording to various STOPP and START criteria varies, and
for only six out of 65 STOPP and two out of 22 START
Table 1 Characteristics of patients according to presence of ≥1 potentially inappropriate medications (PIMs) and/or ≥1 potential prescription
omissions (PPOs), identified by the STOPP and START criteria, respectively
≥1 PIMs/PPOs ≥1 clinically relevant PIMs/PPOs
Yes No Yes No
n = 170 n = 30 P value n = 141 n = 59 P value
Age Mean ± SD 85.1 ± 6.7 81.1 ± 8.3 84.8 ± 6.8 83.7 ± 7.6
Median (range) 85 (65–98) 80 (65–98) 0.009 85 (65–98) 85 (65–98) 0.37
Female sex 112 (66) 21 (70) 0.66 92 (65) 41 (69) 0.56
Multidose drug dispensing 97 (57) 3 (10) <0.0001 86 (61) 14 (24) <0.0001
Impaired cognition 84 (49) 6 (20) 0.003 69 (49) 21 (36) 0.084
Residing in nursing home 56 (33) 4 (13) 0.031 47 (33) 13 (22) 0.11
Number of drugs Mean ± SD 7.7 ± 3.7 4.1 ± 3.7 8.2 ± 3.6 4.8 ± 3.6
Median (range) 7 (0–21) 3 (0–15) <0.0001 8 (2–21) 4 (0–15) <0.0001
Values are presented as number of patients (percentage) if not stated otherwise
SD standard deviation, STOPP screening tool of older person’s potentially inappropriate prescription, START screening tool to alert to right treatment
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criteria, a clinically relevant PIM and PPO, respectively, was
identified in more than 5% of the patients.
In the scientific literature, there are numerous publications
on the prevalence of suboptimal drug treatment according to
various criteria [9]. In a review focusing specifically on the
prevalence of STOPP/START criteria, the figures in various
populations varied between 21 and 79% [10]. Our results are
in the same range as these studies. Nevertheless, our finding
that only half of the identified PIMs/PPOs were clearly clini-
cally relevant at the individual level suggests that estimated
prevalences of suboptimal drug treatment based on these
criteria alone may need to be interpreted with caution.
As a first step to improve the quality of drug treatment in
older people, without taking too much time and effort, physi-
cians may want to consider to stop treatment with long-acting
benzodiazepines and aspirin at doses >150 mg/day. Indeed, in
this study, this kind of treatment could be subject to change in
almost 100% of the cases. Similarly, the use of loop diuretics
without clinical signs of heart failure and vasodilator drugs in
patients with postural hypotension could be worth reconsider-
ation. When it comes to identifying undertreatment and
adding drug(s) to the medication list, it may be a successful
strategy to start off to assess if a patient with cardiovascular
disease would benefit from treatment with an angiotensin
converting enzyme inhibitor, warfarin (or other oral anticoag-
ulants), a beta-blocker, or a statin. Indeed, in seven to eight
cases out of ten without such treatment, information available
in the medical records will suffice to assess the need.
Regarding which patients for physicians to focus upon,
those with multidose drug dispensing were to an increased
extent subjected to suboptimal treatment. This finding sup-
ports previous studies where this system has been associated
with fewer changes in drug treatment, and poorer quality of
drug treatment [19–21]. Further, for those with many drugs,
overtreatment needs to be considered. In fact, the number of
drugs may reflect burden of disease [22], which, in turn, may
Table 2 Potentially inappropriate medications (PIMs) and potential prescription omissions (PPOs), identified by the STOPP and START criteria,
respectively, identified in ≥5% of the study cohort (n ≥ 10)






Benzodiazepines in those prone to falls STOPP 76 (38) 47 (62) 0 (0) 29 (38)
Osteoporosis and no calcium and vitamin D
supplementation
START 61 (31) 10 (16) 4 (7) 47 (77)
Chronic atrial fibrillation without warfarin START 29 (155) 7 (24) 14 (48) 8 (28)
Aspirin with no history of coronary, cerebral or
peripheral arterial symptoms, or occlusive
arterial event
STOPP 27 (14) 13 (48) 12 (44) 2 (7.4)
Aspirin at dose >150 mg day STOPP 24 (12) 23 (96) 1 (4) 0 (0)
Loop diuretic for dependent ankle edema only
i.e., no clinical signs of heart failure
STOPP 24 (12) 20 (83) 0 (0) 4 (17)
Atherosclerotic disease with sinus rhythm
without aspirin or clopidogrel
START 21 (11) 9 (43) 8 (38) 4 (19)
Chronic heart failure without ACE inhibitor START 20 (10) 5 (25) 10 (50) 5 (25)
Diabetes mellitus and ≥1 coexisting major
cardiovascular risk factor without a statin
START 19 (9.5) 4 (21) 11 (58) 4 (21)
Neuroleptic drugs in those prone to falls STOPP 17 (8.5) 11 (65) 0 (0) 6 (35)
Chronic stable angina and no beta-blocker START 17 (8.5) 10 (59) 3 (16) 4 (24)
Vascular disease and a life expectancy of >5
years without a statin
START 16 (8) 9 (56) 2 (13) 5 (31)
Long-term opiates in those with recurrent falls STOPP 16 (8) 9 (56) 0 (0) 7 (44)
Prior acute myocardial infarction and no ACE
inhibitor
START 15 (7.5) 3 (20) 7 (44) 5 (33)
Long-term long-acting benzodiazepines STOPP 13 (6.5) 13 (100) 0 (0) 0 (0)
Vasodilator drugs known to cause hypotension
in those with persistent postural hypotension
STOPP 11 (5.5) 9 (82) 1 (9) 1 (9.1)
Diabetes mellitus and ≥1 coexisting major
cardiovascular risk factor without antiplatelet
therapy
START 11 (5.5) 2 (18) 7 (64) 2 (18)
Maintained oral corticosteroid therapy without
bisphosphonates
START 10 (5) 5 (50) 3 (30) 2 (20)
Values are presented as number of patients (*percentage of all patients; **percentage of patients with PIM/PPO)
ACE angiotensin converting enzyme, STOPP screening tool of older person’s potentially inappropriate prescription, START screening tool to alert to right
treatment
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suggest a greater treatment complexity. Regarding
undertreatment, no significant predictor was identified in the
main analysis, indicating that such treatment needs to be con-
sidered in all cases. Indeed, a previous study has shown that, at
≥2 drugs in the medication list, the number of missing drugs
remains stable irrespective of the number of drugs in the med-
ication list [23]. Interestingly, age and sex were not associated
with clinically relevant PIMs/PPOs, although such an associ-
ation has previously been shown regarding potentially rele-
vant criteria [17]. Further, no significant association with cog-
nition and nursing home residence was found.
In our study, 71% of identified PIMs and 32% of identified
PPOs were considered clinically relevant. These figures are
similar to the implementation rate reported in a recent study:
56 and 39% of PIMs and PPOs, respectively [24]. However,
another study reported that 91% of STOPP and 97% of
START recommendations were accepted by the attending
physician [12]. The divergence between the results may be
explained by the settings of the latter study. In that study, a
research physician discussed recommendations based on
STOPP/START with the attending medical team. Thus,
PIMs/PPOs from the start assessed as not clinically relevant
would probably not be discussed at all due to the medical
expertise of the intervener, and therefore not captured in the
denominator.
The results of this study may contribute to the understand-
ing of the lack of effects for third party medication reviews
regarding patient relevant outcomes reflecting the net effect of
drug treatment, such as death and hospitalizations [25–27]. In
addition to the fact that indicator sets may have a low sensi-
tivity [28, 29], our study shows that only five in ten identified
PIMs/PPOs were clinically relevant, and an additional three
were hard to determine concerning clinical relevance given
easily available information. The latter finding highlights the
importance of a medical assessment of the entire patient as the
basis to determine the appropriateness of drug treatment, in-
cluding the medical history, a physical and/or psychiatric ex-
amination, and laboratory tests. Our findings may also explain
that only a limited proportion of alerts to drug treatment
changes upon third party medication reviews are acted upon
[30].
The most important strengths of this study are that it pro-
vides knowledge on the clinical relevance of the STOPP/
START criteria, and identifies easily manageable advice to
improve drug treatment quality in older people. The results
are strengthened by the fact that the underlying assessments of
clinical relevance were performed by two specialist physicians
with expertise in the relevant area. As could be expected, the
inter-rater agreement was moderate, illustrating the subjectiv-
ity of clinical judgments and the advantage to involve two
assessors.
The fact that we have focused on hip fracture patients may
have implications for the generalizability of the results.
However, these patients may represent a relevant subgroup
of older patients since hip fracture is a common diagnosis in
Sweden where every fourth middle-aged woman will sustain a
hip fracture during her lifetime, and one out of three hip frac-
ture patients is a man [31]. Further, suboptimal drug treatment
is common in this patient group [32]. However, the prevalence
of suboptimal drug treatment, especially inappropriate drugs
related to fall risk, may differ from that found in a general
population of older people, and the results may therefore
Table 3 Odds ratios (95% confidence interval) for ≥1 potentially inappropriate medications (PIMs) and/or ≥1 potential prescription omissions (PPOs),
identified by the STOPP and START criteria, respectively, according to characteristics of the patient
≥1 PIMs/PPOs according to ≥1 clinically relevant PIMs/PPOs according to
STOPP/START STOPP START STOPP/START STOPP START




































Figures in italics represent results in the sensitivity analysis where not assessable PIMs/PPOs were categorized as clinically relevant. Odds ratios which
do not cross the line of unity are underlined
STOPP screening tool of older person’s potentially inappropriate prescription, START screening tool to alert to right treatment, MDD multi-dose drug
dispensing
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mainly be applicable to hip fracture patients and frail older
patients. Another limitation of this study is that the STOPP/
START tools, which were used to systemize the specialist
assessments, may not capture all kinds of suboptimal drug
treatment [24].
In conclusion, this study illustrates the clinical relevance of
the STOPP/START criteria sets, presenting suggestions on
which criteria and which patients to focus upon for a physician
in constraints of time. Indeed, a medical assessment is the key
step when it comes to choosing drug treatment, as all prescrib-
ing has to be adapted to the characteristics of the individual
patient.
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